Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases

Leukemia volume 16, pages 1871–1873 (2002)Cite this article

Hematopoietic growth factors (HGF), particularly G-CSF, are widely used in hematopoietic malignancies to reduce the duration of neutropenia induced by chemotherapy and its subsequent infectious complications. In acute myeloid leukemia (AML), G-CSF or GM-CSF has been used to reduce the duration of neutropenia after induction or consolidation therapy. The benefit of such strategies remains controversial: most studies report a shorter duration of neutropenia with a lower incidence of infections in the HGF arms, but no evidence of reduced mortality.1 When HGF is administered concomitantly with chemotherapy, it recycles leukemic cells and may increase their chemosensitivity. In some studies, patients treated with G-CSF or GM-CSF showed a statistically higher rate of complete remission with improvement of DFS but not overall survival.1,2 These studies demonstrate that G-CSF or GM-CSF may have an anti-leukemic effect. In fact, leukemic cells display HGF receptors and some authors have shown G-CSF-induced apoptosis of leukemic cell.3 Comorbid affections due to advanced age or life-threatening infections associated with leukemia can sometimes postpone chemotherapy. Hematopoietic growth factors may be used to temporarily increase the polymorphonuclear neutrophil (PMN) count in cases of severe infection. Recently, spontaneous complete remission of AML has been reported after treatment with G-CSF alone without chemotherapy.4 In all cases patients had concomitant infections except one case reported by Ferrara et al.5 We report on three AML patients without infections who entered CR after initial treatment with G-CSF alone. Cytogenetic remission was documented in one case.

Case 1: A 68-year-old woman was admitted for pancytopenia in March 2000. She presented with ulceronecrotic pharyngitis and fever. Physical examination was normal. Blood count on diagnosis showed: WBC 0.5 × 109/l (PMN: 10%, lymphocytes: 90%), no circulating blast cells, Hb 3.5 g/dl, platelets 62 × 109 /l. Bone marrow examination revealed hypocellular marrow with 30% of blast cells, expressing MPO and CD33, CD13, CD34 antigens. Acute myeloid leukemia (AML-M2) was diagnosed. Karyotype revealed 46XX del 7q11, del 13q in 14 mitoses and a normal pattern in 12 mitoses. Due to severe neutropenia associated with marrow hypoplasia without blastic proliferation, it was decided to treat with G-CSF alone. Lenograstime rhuG-CSF 263 μg (Granocyte 34; Chugai Pharma, France) was administered subcutaneously daily. Two weeks later, WBC increased to 1.6 × 109/l with 60% PMN, Hb 10 g/dl, no circulating blast cells, platelets 90 × 109/l. G-CSF was continued at a dose of 105 μg (Granocyte 13) three times a week. Six weeks after starting therapy, blood count showed: 9.3 × 109/l (PMN: 90%, lymphocytes: 10%), Hb 10 g/dl, platelets 261 × 109/l, and no circulating blast cells. Bone marrow examination was normocellular with less than 5% blast cells. The cytogenetic analysis was normalized with disappearance of the abnormal clone. The patient had achieved complete remission with G-CSF alone and died from relapse.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzanneau G, Tilly H, Yver A, Degos L . A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia N Engl J Med 1995 332: 1678–1683

    Article  CAS  Google Scholar 

  2. Bernasconi C, Alessandrino EP, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A, Castelli G, Brusamolino E, Pagnucco G, Castagnola C . Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high risk myelodysplastic syndromes or secondary acute leukemia evolving from MDS Br J Haematol 1998 102: 678–683

    Article  CAS  Google Scholar 

  3. Fujiwara H, Arma N, Matsushita K, Hidaka S, Ohtsubo H, Fukumori J, Arimura K, Kukita T, Tanaka H . Granulocyte-colony stimulating factor induces differentiation and apoptosis of CD2, CD7 positive hybrid leukemia cells in vivo and ex vivo Leukemia Res 1997 21: 735–741

    Article  CAS  Google Scholar 

  4. Takamatsu Y, Miyamoto T, Iwasaki H, Makino S, Tamura K . Remission induction by granulocyte colony stimulating factor in hypoplastic acute myelogenous leukemia complicated by infection Acta Haematol 1998 99: 224–230

    Article  CAS  Google Scholar 

  5. Ferrara F, Di Noto R, Viola A, Russo C, Boccuni P, Costantini S, Dello Russo A, Lo Pardo C, Del Vecchio L . Complete remission in acute myeloid leukemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation Br J Haematol 1999 106: 520–523

    Article  CAS  Google Scholar 

  6. Takahashi M, Koike T, Aizawa Y, Kashimura M, Hayatsu K, Nagai K, Abe A, Urushiyama M, Yagisawa K . Complete remission in three patients with acute myeloblastic leukemia by administration of G-CSF without antileukemic agents Am J Hematol 1997 56: 42–44

    Article  CAS  Google Scholar 

  7. Da Silva N, Meyer-Monard S, Meno ML, Parrado A, Lebel A, Balitrand N, Fenaux P, Micléa JM, Rousselot P, Degos L, Dombret H, Chomienne C . Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation and degradation of AML1-ETO Hematol J 2000 1: 316–328

    Article  CAS  Google Scholar 

  8. Bishop MR, Torantolo SR, Pavletic ZS, Lynch JC, Moris ME, Zacharias D, Armitage JO, Kessinger A . Filgrastim as an alternative to donor leukocyte infusion for relapse after allogenic stem-cell transplantation J Clin Oncol 2000 18: 2269–2272

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Hématologie Clinique, CHU de Rennes, France

    S Nimubona, I Grulois, M Bernard & T Lamy

  2. Unité d'Onco-Hématologie, CH de Saint-Malo, France

    I Grulois

  3. Laboratoire d'Hématologie, CHU de Rennes, France

    B Drénou, M Godard & R Fauchet

Authors
  1. S Nimubona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Grulois
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Drénou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Godard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Fauchet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Lamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nimubona, S., Grulois, I., Bernard, M. et al. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: report on three cases. Leukemia 16, 1871–1873 (2002). https://doi.org/10.1038/sj.leu.2402592

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402592

This article is cited by

Search

Advanced search

Quick links